Global Cancer Stem Cell Market Growth (Status and Outlook) 2023-2029

Global Cancer Stem Cell Market Growth (Status and Outlook) 2023-2029

Cancer stem cells (CSCs) refer to the cells obtained from tumor that posses potential to reproduce all types of cancer cells found in a cancer sample. Cancer stem cells are planned to grow in tumors as a separate population and thereby cause deterioration and metastasis of existing tumor through generation of new tumor. Thus, with advancement in technology especially in cancer stem cells research area, therapies specific to targeting cancer stem cells are expected to improve quality of life and survival cases of cancer patients with metastatic diseases.

LPI (LP Information)' newest research report, the “Cancer Stem Cell Industry Forecast” looks at past sales and reviews total world Cancer Stem Cell sales in 2022, providing a comprehensive analysis by region and market sector of projected Cancer Stem Cell sales for 2023 through 2029. With Cancer Stem Cell sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cancer Stem Cell industry.

This Insight Report provides a comprehensive analysis of the global Cancer Stem Cell landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Stem Cell portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cancer Stem Cell market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Stem Cell and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Stem Cell.

The global Cancer Stem Cell market size is projected to grow from US$ 1033.3 million in 2022 to US$ 1758.9 million in 2029; it is expected to grow at a CAGR of 7.9% from 2023 to 2029.

North America was the leading revenue contributor of the cancer stem cells market in 2016 due to presence of a substantial number of organizations engaged in conducting R&D activities related to stem cell therapy. There are several internationally recognized hospitals and medical institutes, such as Cancer Treatment Centers of America at Midwestern Regional Medical Center, which offer stem cell transplant therapies.

Asia Pacific is expected to be a promising region in the arena owing to presence of several organizations in the region that focus on R&D of stem cells. Moreover, funding agencies are providing grants to research communities to accelerate their scientific research on cancer stem cells in Asian countries.

This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Stem Cell market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Cell Culturing
Cell Separation
Cell Analysis
Molecular Analysis
Others

Segmentation by application
Stem Cell Based Cancer Therapy
Targeted CSCs

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Thermo Fisher Scientific, Inc.
AbbVie, Inc.
Merck KGaA
Bionomics
Lonza
Stemline Therapeutics, Inc.
Miltenyi Biotec
PromoCell GmbH
MacroGenics, Inc.
OncoMed Pharmaceuticals, Inc.
Irvine Scientific
STEMCELL Technologies Inc.
Sino Biological Inc.
BIOTIME, Inc.

Please note: The report will take approximately 2 business days to prepare and deliver.